2-(3,5-Dimethyl-phenoxy)-4-[5-(4-fluoro-phenyl)-3-piperidin-4-yl-3H-imidazol-4-yl]-pyrimidine

ID: ALA417255

Chembl Id: CHEMBL417255

Cas Number: 219769-23-0

PubChem CID: 18536633

Max Phase: Preclinical

Molecular Formula: C26H26FN5O

Molecular Weight: 443.53

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cc1cc(C)cc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1

Standard InChI:  InChI=1S/C26H26FN5O/c1-17-13-18(2)15-22(14-17)33-26-29-12-9-23(31-26)25-24(19-3-5-20(27)6-4-19)30-16-32(25)21-7-10-28-11-8-21/h3-6,9,12-16,21,28H,7-8,10-11H2,1-2H3

Standard InChI Key:  UVLWMBRFRAMDOW-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA417255

   2-(3,5-Dimethylphenoxy)-4-[1-(piperidine-4-yl)-4-(4-fluorophenyl)-5-imidazolyl]pyrimidine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 443.53

Molecular Weight (Monoisotopic): 443.2121

AlogP: 5.48

#Rotatable Bonds: 5

Polar Surface Area: 64.86

Molecular Species: BASE

HBA: 6

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 10.13

CX LogP: 5.13

CX LogD: 2.52

Aromatic Rings: 4

Heavy Atoms: 33

QED Weighted: 0.44

Np Likeness Score: -0.98

References

1. Boehm JC, Bower MJ, Gallagher TF, Kassis S, Johnson SR, Adams JL..  (2001)  Phenoxypyrimidine inhibitors of p38alpha kinase: synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles.,  11  (9): [PMID:11354358] [10.1016/s0960-894x(01)00163-9]

2. Ravindra GK, Achaiah G, Sastry GN..  (2008)  Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.,  43  (4): [PMID:17706839] [10.1016/j.ejmech.2007.06.009]

3. Simon Townson and Suzanne Gokool. GlaxoSmithKline Published Kinase Inhibitor Set 2 Onchocerca lienalis Screening Data,  [10.6019/CHEMBL3988181]

4. Divakaran A, Talluri SK, Ayoub AM, Mishra NK, Cui H, Widen JC, Berndt N, Zhu JY, Carlson AS, Topczewski JJ, Schonbrunn EK, Harki DA, Pomerantz WCK..  (2018)  Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.,  61  (20): [PMID:30253095] [10.1021/acs.jmedchem.8b01248]

5. Cui H, Divakaran A, Hoell ZJ, Ellingson MO, Scholtz CR, Zahid H, Johnson JA, Griffith EC, Gee CT, Lee AL, Khanal S, Shi K, Aihara H, Shah VH, Lee RE, Harki DA, Pomerantz WCK..  (2022)  A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.,  65  (3.0): [PMID:35007061] [10.1021/acs.jmedchem.1c01779]

6. Fu Y, Zhang Y, Sun H..  (2021)  Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.,  226  [PMID:34547507] [10.1016/j.ejmech.2021.113853]

Source

Source(2):

• Scientific Literature
• Published Kinase Inhibitor Set 2